```
=> d his ful

     (FILE 'REGISTRY' ENTERED AT 11:40:51 ON 25 SEP 2007)
L3                STR
L5             37 SEA SSS FUL L3
L10               STR
L11               STR
L12            37 SEA SUB=L5 SSS FUL L3 NOT (L10 OR L11)

     FILE 'HCAPLUS' ENTERED AT 12:49:24 ON 25 SEP 2007
L13             1 SEA ABB=ON  PLU=ON  L12
                  D STAT QUE L13
                  D IBIB ABS HITSTR L13 1
L14            83 SEA ABB=ON  PLU=ON  ("BEYER T"/AU OR "BEYER T A"/AU) OR "BEYER
                  TH"/AU OR ("BEYER THOMAS"/AU OR "BEYER THOMAS A"/AU OR "BEYER
                  THOMAS ARTHUR"/AU)
L15           164 SEA ABB=ON  PLU=ON  CHAMBERS R/AU OR  CHAMBERS R J/AU OR
                  CHAMBERS ROBERT/AU OR CHAMBERS ROBERT J/AU OR CHAMBERS ROBERT
                  JAMES/AU
L16            69 SEA ABB=ON  PLU=ON  LAM K/AU OR LAM K T/AU OR LAM KELVIN ?/AU
L17          1264 SEA ABB=ON  PLU=ON  LI M ?/AU OR LI MEI ?/AU
L18            36 SEA ABB=ON  PLU=ON  "MORRELL ANDREW"/AU OR ("MORRELL ANDREW
                  I"/AU OR "MORRELL ANDREW IAN"/AU)
L19           433 SEA ABB=ON  PLU=ON  THOMPSON D/AU OR THOMPSON D D/AU OR
                  "THOMPSON DAVID"/AU OR THOMPSON DAVID D?/AU
L20             1 SEA ABB=ON  PLU=ON  L14 AND (L15 OR L16 OR L17 OR L18 OR L19)
L21             4 SEA ABB=ON  PLU=ON  L15 AND (L16 OR L17 OR L18 OR L19)
L22             0 SEA ABB=ON  PLU=ON  L16 AND (L17 OR L18 OR L19)
L23             0 SEA ABB=ON  PLU=ON  L17 AND (L18 OR L19)
L24             1 SEA ABB=ON  PLU=ON  L18 AND L19
L25             4 SEA ABB=ON  PLU=ON  L20 OR L21 OR L22 OR L23 OR L24
                  D STAT QUE L25
                  D IBIB ABS HITSTR L25 1-4



     FILE HCAPLUS

     Copyright of the articles to which records in this database refer is
     held by the publishers listed in the PUBLISHER (PB) field (available
     for records published or updated in Chemical Abstracts after December
     26, 1996), unless otherwise indicated in the original publications.
     The CA Lexicon is the copyrighted intellectual property of the
     the American Chemical Society and is provided to assist you in searching
     databases on STN.  Any dissemination, distribution, copying, or storing
     of this information, without the prior written consent of CAS, is
     strictly prohibited.

     FILE COVERS 1907 - 25 Sep 2007  VOL 147 ISS 14
     FILE LAST UPDATED: 24 Sep 2007  (20070924/ED)

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

      This file contains CAS Registry Numbers for easy and accurate
      substance identification.

     FILE REGISTRY
```

```
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:   24 SEP 2007  HIGHEST RN 947820-54-4
     DICTIONARY FILE UPDATES:  24 SEP 2007  HIGHEST RN 947820-54-4

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

     TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

       Please note that search-term pricing does apply when
       conducting SmartSELECT searches.

     REGISTRY includes numerically searchable data for experimental and
     predicted properties as well as tags indicating availability of
     experimental property data in the original document.  For information
     on property searching in REGISTRY, refer to:

     http://www.cas.org/support/stngen/stndoc/properties.html

=>
=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 12:49:24 ON 25 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 25 Sep 2007  VOL 147 ISS 14
FILE LAST UPDATED: 24 Sep 2007  (20070924/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=>
=>

=> d stat que l13
L3              STR
```



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 22

STEREO ATTRIBUTES: NONE
L5 37 SEA FILE=REGISTRY SSS FUL L3
L10 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 22

STEREO ATTRIBUTES: NONE
L11 STR



```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  24

STEREO ATTRIBUTES: NONE
L12          37 SEA FILE=REGISTRY SUB=L5 SSS FUL L3 NOT (L10 OR L11)
L13           1 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L12


=>
=>

=> d ibib abs hitstr l13 1

L13  ANSWER 1 OF 1  HCAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2005:588963  HCAPLUS  Full-text
DOCUMENT NUMBER:          143:115560
TITLE:                    Preparation of pyrido[2,3-d]pyrimidine-2,4-diamines as
                          PDE-2 inhibitors
INVENTOR(S):              Beyer, Thomas Arthur; Chambers, Robert James; Lam,
                          Kelvin; Li, Mei; Morrell, Andrew Ian; Thompson, David
                          Duane
PATENT ASSIGNEE(S):       Pfizer Products Inc., USA
SOURCE:                   PCT Int. Appl., 48 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.            KIND   DATE        APPLICATION NO.          DATE
     ---------------       ----   --------    --------------------     --------
     WO 2005061497          A1    20050707    WO 2004-IB4013           20041206
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
```

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU	2004303609	A1	20050707	AU 2004-303609	20041206
CA	2549510	A1	20050707	CA 2004-2549510	20041206
EP	1697356	A1	20060906	EP 2004-801323	20041206
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
CN	1894245	A	20070110	CN 2004-80037674	20041206
BR	2004017663	A	20070403	BR 2004-17663	20041206
JP	2007513996	T	20070531	JP 2006-544574	20041206
NL	1027787	A1	20050621	NL 2004-1027787	20041215
NL	1027787	C2	20060309		
US	2007135457	A1	20070614	US 2006-595766	20060510
IN	2006DN02850	A	20070810	IN 2006-DN2850	20060519
MX	2006PA06777	A	20060823	MX 2006-PA6777	20060615
NO	2006003231	A	20060711	NO 2006-3231	20060711

PRIORITY APPLN. INFO.: US 2003-529994P P 20031216
WO 2004-IB4013 W 20041206

GI



AB Title compds. I [Z = O-alkyl; R1, R2 = H, OCH3 with provisos; n = 1-4; X = a bond, O, S, etc.; Y = benzoxazolyl, benzothiazolyl, benzofurazanyl, etc.] and their pharmaceutically acceptable salts were prepared For example, aminoarom. substitution of chloropyrimide II and 2-(2-aminoethyl)pyridine afforded pyrido[2,3-d]pyrimidine III in 40% yield. In PDE 2 inhibition assays, 4 - examples of compds. I exhibited IC50 values <50 nM.

IT 857521-01-8P 857521-02-9P 857521-03-0P
857521-04-1P 857521-05-2P 857521-06-3P
857521-07-4P 857521-08-5P 857521-09-6P
857521-10-9P 857521-11-0P 857521-12-1P

857521-13-2P 857521-14-3P 857521-15-4P
857521-16-5P 857521-17-6P 857521-18-7P
857521-19-8P 857521-20-1P 857521-21-2P
857521-22-3P 857521-23-4P 857521-24-5P
857521-25-6P 857521-26-7P 857521-27-8P
857521-28-9P 857521-29-0P 857521-30-3P
857521-31-4P 857521-32-5P 857521-33-6P
857521-34-7P 857521-35-8P 857521-36-9P
857521-37-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrido[2,3-d]pyrimidine-2,4-diamines as PDE-2 inhibitors)

RN 857521-01-8 HCAPLUS

CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-[2-(2-pyridinyl)ethyl]- (CA INDEX NAME)



RN 857521-02-9 HCAPLUS

CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-[2-(3-pyridinyl)ethyl]- (CA INDEX NAME)



RN 857521-03-0 HCAPLUS

CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)



RN 857521-04-1 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 857521-05-2 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N,N'-bis[(3,5-dimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 857521-06-3 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-[2-(4-methoxyphenyl)ethyl]- (CA INDEX NAME)



RN 857521-07-4 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-(3-phenylpropyl)- (CA INDEX NAME)



RN 857521-08-5 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N2-[(4-chlorophenyl)methyl]-N4-[(3,5-dimethoxyphenyl)methyl]- (CA INDEX NAME)



RN 857521-09-6 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-(phenylmethyl)- (CA INDEX NAME)



RN 857521-10-9 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-[2-(2-thienyl)ethyl]- (CA INDEX NAME)



RN 857521-11-0 HCAPLUS
CN Benzenemethanol, 4-[[[4-[[(3,5-dimethoxyphenyl)methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]methyl]-α,α-dimethyl- (CA INDEX NAME)



RN 857521-12-1 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-(2-phenylethyl)- (CA INDEX NAME)



RN 857521-13-2 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N2-[2-(3,5-dimethoxyphenyl)ethyl]-N4-[(3,5-dimethoxyphenyl)methyl]- (CA INDEX NAME)



RN 857521-14-3 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,4-dimethoxyphenyl)methyl]-N2-[2-(3-fluorophenyl)ethyl]- (CA INDEX NAME)



RN 857521-15-4 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,4-dimethoxyphenyl)methyl]-N2-[2-(2-fluorophenyl)ethyl]- (CA INDEX NAME)



RN 857521-16-5 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,4-dimethoxyphenyl)methyl]-N2-[2-(4-fluorophenyl)ethyl]- (CA INDEX NAME)



RN 857521-17-6 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,4-dimethoxyphenyl)methyl]-N2-(2-phenylethyl)- (CA INDEX NAME)



RN 857521-18-7 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,4-dimethoxyphenyl)methyl]-N2-(4-phenylbutyl)- (CA INDEX NAME)



RN 857521-19-8 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,4-dimethoxyphenyl)methyl]-N2-(2-phenoxyethyl)- (CA INDEX NAME)



RN 857521-20-1 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,4-dimethoxyphenyl)methyl]-N2-[[2-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 857521-21-2 HCAPLUS
CN Benzenemethanol, 4-[2-[[4-[[(3,4-dimethoxyphenyl)methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]ethyl]-α,α-dimethyl- (CA INDEX NAME)



RN 857521-22-3 HCAPLUS
CN Benzenemethanol, 4-[2-[[4-[[(3,5-dimethoxyphenyl)methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]ethyl]-α,α-dimethyl- (CA INDEX NAME)



RN 857521-23-4 HCAPLUS
CN Benzenemethanol, 4-[[[4-[[(3,5-dimethoxyphenyl)methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]methyl]-α-(trifluoromethyl)- (CA INDEX NAME)



RN 857521-24-5 HCAPLUS

CN Ethanone, 1-[4-[3-[[4-[[(3,4-dimethoxyphenyl)methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]propyl]phenyl]- (CA INDEX NAME)



RN 857521-25-6 HCAPLUS

CN Benzenemethanol, 4-[3-[[4-[[(3,4-dimethoxyphenyl)methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]propyl]-α-(trifluoromethyl)- (CA INDEX NAME)



RN 857521-26-7 HCAPLUS

CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N2-[3-(2,1,3-benzoxadiazol-5-yl)propyl]-N4-[(3,4-dimethoxyphenyl)methyl]-



RN 857521-27-8 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N2-[3-(6-benzothiazolyl)propyl]-N4-[(3,4-dimethoxyphenyl)methyl]- (CA INDEX NAME)



RN 857521-28-9 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,4-dimethoxyphenyl)methyl]-N2-[3-[3-(2-methyl-1,3-dioxolan-2-yl)phenyl]propyl]- (CA INDEX NAME)



RN 857521-29-0 HCAPLUS
CN Benzenemethanol, 3-[3-[[4-[[(3,4-dimethoxyphenyl)methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]propyl]-α-methyl- (CA INDEX NAME)



RN 857521-30-3 HCAPLUS
CN Benzonitrile, 4-[3-[[4-[[(3,4-dimethoxyphenyl)methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]propyl]- (CA INDEX NAME)



RN 857521-31-4 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-[3-(4-pyridinyl)propyl]- (CA INDEX NAME)



RN 857521-32-5 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,4-dimethoxyphenyl)methyl]-N2-(3-phenylpropyl)- (CA INDEX NAME)



RN 857521-33-6 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-(3-phenoxypropyl)- (CA INDEX NAME)



RN 857521-34-7 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3-ethoxy-4-methoxyphenyl)methyl]-N2-(3-phenylpropyl)- (CA INDEX NAME)



RN 857521-35-8 HCAPLUS
CN Benzenemethanol, 4-[3-[[4-[[(3-ethoxy-4-methoxyphenyl)methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]propyl]-α-methyl- (CA INDEX NAME)



RN 857521-36-9 HCAPLUS
CN Ethanone, 1-[4-[3-[[4-[[(3,4-dimethoxyphenyl)methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]propyl]phenyl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 857521-37-0 HCAPLUS
CN Ethanone, 1-[3-[3-[[4-[[(3,4-dimethoxyphenyl)methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]propyl]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> => d stat que l25
L14          83 SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("BEYER T"/AU OR "BEYER T
                A"/AU) OR "BEYER TH"/AU OR ("BEYER THOMAS"/AU OR "BEYER THOMAS
                A"/AU OR "BEYER THOMAS ARTHUR"/AU)
L15         164 SEA FILE=HCAPLUS ABB=ON  PLU=ON  CHAMBERS R/AU OR  CHAMBERS R
                J/AU OR CHAMBERS ROBERT/AU OR CHAMBERS ROBERT J/AU OR CHAMBERS
                ROBERT JAMES/AU
L16          69 SEA FILE=HCAPLUS ABB=ON  PLU=ON  LAM K/AU OR LAM K T/AU OR LAM
                KELVIN ?/AU
L17        1264 SEA FILE=HCAPLUS ABB=ON  PLU=ON  LI M ?/AU OR LI MEI ?/AU
L18          36 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "MORRELL ANDREW"/AU OR
                ("MORRELL ANDREW I"/AU OR "MORRELL ANDREW IAN"/AU)
L19         433 SEA FILE=HCAPLUS ABB=ON  PLU=ON  THOMPSON D/AU OR THOMPSON D
                D/AU OR "THOMPSON DAVID"/AU OR THOMPSON DAVID D?/AU
L20           1 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L14 AND (L15 OR L16 OR L17 OR
                L18 OR L19)
L21           4 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L15 AND (L16 OR L17 OR L18 OR
                L19)
L22           0 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L16 AND (L17 OR L18 OR L19)
L23           0 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L17 AND (L18 OR L19)
L24           1 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L18 AND L19
L25           4 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L20 OR L21 OR L22 OR L23 OR
                L24


=>
=>

=> d ibib abs hitstr l25 1-4

L25  ANSWER 1 OF 4  HCAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2005:1341994  HCAPLUS  Full-text
DOCUMENT NUMBER:          144:145269
TITLE:                    A new chemical tool for exploring the role of the
                          PDE4D isozyme in leukocyte function
AUTHOR(S):                Chambers, Robert J.; Abrams, Kristin;
                          Castleberry, Tessa A.; Cheng, John B.; Fisher, Douglas
                          A.; Kamath, Ajith V.; Marfat, Anthony; Nettleton,
                          David O.; Pillar, Joann D.; Salter, Eben D.; Sheils,
                          Alissa L.; Shirley, John T.; Turner, Claudia R.;
                          Umland, John P.; Lam, Kelvin T.
CORPORATE SOURCE:         Groton Laboratories, Pfizer, Inc., Groton, CT, 06340,
                          USA
SOURCE:                   Bioorganic & Medicinal Chemistry Letters (2006),
                          16(3), 718-721
                          CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER:                Elsevier B.V.
DOCUMENT TYPE:            Journal
LANGUAGE:                 English
OTHER SOURCE(S):          CASREACT 144:145269
AB    A nicotinamide derivative is a potent and selective inhibitor of the cAMP
      phosphodiesterase 4D isoenzyme and as a chemical tool selectively blocks
      eosinophil mediator release and chemotaxis thus linking the role of PDE4D to
      eosinophil function.
REFERENCE COUNT:          37    THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS
```

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1251608 HCAPLUS Full-text
DOCUMENT NUMBER: 144:100367
TITLE: A new chemical tool for exploring the physiological function of the PDE2 isozyme
AUTHOR(S): Chambers, Robert J.; Abrams, Kristin; Garceau, Norman Y.; Kamath, Ajith V.; Manley, Christopher M.; Lilley, Susan C.; Otte, Douglas A.; Scott, Dennis O.; Sheils, Alissa L.; Tess, David A.; Vellekoop, A. Samuel; Zhang, Yan; Lam, Kelvin T.
CORPORATE SOURCE: Research Technology Center, Pfizer, Inc., Cambridge, MA, 02139, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(2), 307-310
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 144:100367
AB Oxindole (2) is a potent and selective PDE2 inhibitor with a favorable ADME, physiochem. and pharmacokinetic profile to allow for use as a chemical tool in elucidating the physiol. role of PDE2.
REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:588963 HCAPLUS Full-text
DOCUMENT NUMBER: 143:115560
TITLE: Preparation of pyrido[2,3-d]pyrimidine-2,4-diamines as PDE-2 inhibitors
INVENTOR(S): Beyer, Thomas Arthur; Chambers, Robert James; Lam, Kelvin; Li, Mei; Morrell, Andrew Ian; Thompson, David Duane
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005061497	A1	20050707	WO 2004-IB4013	20041206
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

AU 2004303609	A1	20050707	AU 2004-303609		20041206
CA 2549510	A1	20050707	CA 2004-2549510		20041206
EP 1697356	A1	20060906	EP 2004-801323		20041206
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU					
CN 1894245	A	20070110	CN 2004-80037674		20041206
BR 2004017663	A	20070403	BR 2004-17663		20041206
JP 2007513996	T	20070531	JP 2006-544574		20041206
NL 1027787	A1	20050621	NL 2004-1027787		20041215
NL 1027787	C2	20060309			
US 2007135457	A1	20070614	US 2006-595766		20060510
IN 2006DN02850	A	20070810	IN 2006-DN2850		20060519
MX 2006PA06777	A	20060823	MX 2006-PA6777		20060615
NO 2006003231	A	20060711	NO 2006-3231		20060711
PRIORITY APPLN. INFO.:			US 2003-529994P	P	20031216
			WO 2004-IB4013	W	20041206

GI



AB Title compds. I [Z = O-alkyl; R1, R2 = H, OCH3 with provisos; n = 1-4; X = a bond, O, S, etc.; Y = benzoxazolyl, benzothiazolyl, benzofurazanyl, etc.] and their pharmaceutically acceptable salts were prepared For example, aminoarom. substitution of chloropyrimide II and 2-(2-aminoethyl)pyridine afforded pyrido[2,3-d]pyrimidine III in 40% yield. In PDE 2 inhibition assays, 4 - examples of compds. I exhibited IC50 values <50 nM.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:	2005:409310 HCAPLUS Full-text
DOCUMENT NUMBER:	142:463708
TITLE:	Preparation of oxindole derivatives and their use as phosphodiesterase type 2 inhibitors
INVENTOR(S):	Chambers, Robert James; Lam, Kaivin

T.

PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005041957	A1	20050512	WO 2004-IB3404	20041018

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-515406P P 20031029
OTHER SOURCE(S): CASREACT 142:463708; MARPAT 142:463708
GI



I



II

AB The present invention provides compds. I [R1 = alkyl; R2 = H, alkyl; R3 = thiazolyl, isothiazolyl, thiadiazolyl, etc.; X = S, O; Y = C, N], methods and kits for treatment of disease states or disorders mediated by PDE2. Syntheses of over 10 compds. I is given. Thus, amidation of Et 5-methyl-6-oxo-6,7-dihydro-5H-1-oxa-5-aza-s-indacene-7-carboxylate with 2-amino-5-methyl-1,3,4-thiadiazole afforded 25% II which showed IC50 of <0.2 μM against PDE2.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>